Fecal microbiota transplantation in clinical practice:Present controversies and future prospects  

作　　者：Hongliang Tian Xinjun Wang Zhixun Fang Long Li Chunyan Wu Dexi Bi Ning Li Qiyi Chen Huanlong Qin 

机构地区：[1]Department of Colorectal Disease,Tenth People’s Hospital of Tongji University,Shanghai,China [2]Shanghai Institution of Gut Microbiota Research and Engineering Development,Tenth People’s Hospital of Tongji University,Shanghai,China [3]Clinical Research Center for Digestive Diseases,Tongji University,Shanghai,China [4]Bengbu First People’s Hospital,Anhui,China [5]Research Institute of Intestinal Diseases,Tongji University School of Medicine,Shanghai,China [6]Department of Pathology,Tenth People’s Hospital of Tongji University,Shanghai,China [7]Realbio Genomics Institute,Shanghai,China

出　　处：《hLife》2024年第6期269-283,共15页健康科学（英文）

基　　金：This study was supported by the National NaturalScience Foundation of China(81972221,81730102,and 82300753);China postdoctoral science foundation(2022M722412);Top priority project of Shanghai(076478684Q/2023-00154);Major project of Zhangjiang(ZJ2022-ZD-005);Clinical Research Plan of SHDC(SHDC2020CR4026,SHDC2020CR1030B,and SHDC2022CRS041);Project of Shanghai Science and Technology Commission(YDZX20213100003690);Project of Shanghai Municipal Health Commission(19YF1431000 and ZHYY-ZXYJHZX-202105);Anhui Provincial Key R&D Programmes(202304295107020025);Climb Plan of Tenth People’s Hospital of Tongji University(2021SYPDRC045).

摘　　要：The gut microbiota,serving as the only“organ”that humans can share,has been extensively applied in the treatment of various intestinal and extraintestinal diseases through fecal microbiota transplantation(FMT)technology.By optimizing the donor selection strategy,FMT exhibited the highest effectiveness(more than 90%)in treating acute intestinal inflammations,such as recurrent Clostridium difficile infection.However,the efficacy diminishes when addressing intestinal functional diseases(more than 60%),chronic intestinal inflammations or organic diseases(less than 60%),and extraintestinal diseases,particularly those lacking any gastrointestinal symptoms(less than 50%).Ongoing efforts to enhance the therapeutic response of FMT across diverse diseases represent a central focus of current clinical research.This review concentrates on donor selection,recipient management,precise donor-recipient matching,antagonistic mechanism of native bacteria to transplanted bacteria,and targeted treatment strategies for different diseases,with the aim of providing practical strategies to improve the clinical efficacy of FMT.

关 键 词：fecal microbiota transplantation clinical research colonization antagonism 

分 类 号：R446.13[医药卫生—诊断学]